iSpecimen Reports Full Year 2021 Financial Results

Rhea-AI Summary

iSpecimen Inc. (Nasdaq: ISPC) reported a record FY 2021 revenue of $11.1 million, a 36% increase from FY 2020's $8.2 million. The revenue consisted of $8.0 million (72%) from non-COVID-19 related sources and $3.1 million (28%) from COVID-19. The company expanded its supplier network to 200 organizations and customer purchases grew to 415. iSpecimen raised $21 million in a private placement, enhancing its capabilities for biospecimen research. However, net loss increased to $9.0 million from $4.7 million in 2020.

Positive

• Record FY 2021 revenue of $11.1 million, a 36% increase from FY 2020.
• 72% of revenue from non-COVID-19 related activities, showing diversification.
• Expanded supplier network to 200 organizations, increasing capacity.
• Raised $21 million in a private placement to accelerate growth.

Negative

• Net loss increased to $9.0 million from $4.7 million in FY 2020.
• Cost of revenue rose to $5.2 million, driven by a 56% increase in average specimen cost.
• General and administrative expenses surged to $5.6 million, reflecting public company costs.

Record FY 2021 Revenue of $11.1 Million, Surpassing FY 2020 Revenue of $8.2 Million by 36%

LEXINGTON, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online marketplace for human biospecimens, today reported its financial results for the three and twelve-month periods ended December 31, 2021.

“iSpecimen achieved significant milestones in 2021. During the year, we successfully closed our IPO and began trading on the NASDAQ, raised $21 million in a private placement to advance the development of our Marketplace platform and expanded our supplier network,” said Christopher Ianelli, MD, PhD, CEO and President of iSpecimen. “Collectively, these milestones and accomplishments will help iSpecimen advance its efforts to address the highly fragmented global biospecimen procurement challenge, as well as strategically position the Company for further growth.”

Dr. Ianelli added, “Throughout 2022, we expect to further develop the iSpecimen Marketplace platform by expanding our supplier network, investing in technology and datasets, and assessing opportunities to alleviate supply constraints. At the same time, we are prepared to pursue accretive growth opportunities.”

FY 2021 Financial & Operational Highlights

• Revenue increased 36% to $11.1 million for the FY 2021, compared to $8.2 million for FY 2020.
• FY 2021 revenue mix comprised of $8.0 million of non-COVID-19 related revenue, or 72% of revenue, and $3.1 million of COVID-19 related revenue, or 28% of revenue, compared to the same period a year ago with a revenue mix of 57% of non-COVID-19 related revenue and 43% of COVID-19 related revenue
• Unique supplier organizations under agreement were 200 as of December 31, 2021, an increase from 181 as of December 31, 2020.
• Unique customer organizations with purchases totaled 415 as of December 31, 2021, an increase of 26% from 330 at the end of 2020.
• iSpecimen Marketplace had more than 5,000 registered research and supplier users as of December 31, 2021, up 33% year-over-year.
  

Recent Corporate Updates

• Contracted by U.S. Government and private researchers to supply critical human biospecimens to support new advanced research on COVID-19 seeking insights on its transmissibility, variants, outcomes, and testing validity among multiple population segments.
  
  
• Raised $21 million in a private placement in December 2021. The Company is well positioned to accelerate growth through both organic and inorganic growth strategies.
  
  
• Expanded supplier network of human biospecimens to help advance research in neurological disorders. iSpecimen has added more than a dozen sample providers to its network of suppliers that provide access to banked or custom collections of biospecimens such as cerebrospinal fluid, other biofluids, or cells to help advance CNS research.
  
  
• Expanded its global provider network footprint, with roughly 25% of new suppliers added in 2021 coming from outside the United States.
  
  
• Enhanced COVID-19 research with the addition of a reference lab in New York to provide sequenced specimens to detect variants. The expansion of its supplier capabilities support commercial and government customers focused on COVID-19 research, including analyzing the Omicron and Delta variants.
  

Financial Results for the Full Year 2021

Revenue for the full year 2021 increased 36% to $11.1 million, compared to $8.2 million during the full year 2020. The increase in revenue was primarily attributable to the success of our maturing sales team. For the full year 2021, non-COVID-19 related revenue was approximately $8.0 million, or 72% of revenue, compared to approximately $4.7 million, or 57% of our revenue for the comparable 2020 period. For the full year 2021, COVID-19 related revenue was approximately $3.1 million, or 28% of revenue, compared to approximately $3.5 million, or 43% of our revenue for the comparable period in 2020.

Cost of revenue was $5.2 million for the full year 2021, compared to $3.6 million for the full year 2020. This was attributable to a 56% increase in the average cost per specimen offset by a 6% decrease in the number of specimens accessioned during the same current twelve-month period over the same prior year period.

General and administrative expenses were $5.6 million, compared to $2.4 million during the same period last year. The increase in costs were primarily attributable to becoming a public company, including director and officer insurance, as well as increased costs in all other general and administrative areas such as human resources, outsourced information technology and software licenses, loss on sale of accounts receivable and allowance for doubtful accounts.

Net loss was approximately $9.0 million for the full year 2021, compared to net loss of over $4.7 million for the same period in 2020.

Cash was approximately $27.7 million as of December 31, 2021.

* The financial information presented in this press release is based on preliminary unaudited financial statements prepared by management, for the year ended December 31, 2021, and is fully qualified by the section in this press release entitled ‘Disclaimer Regarding Financial Information.'

Conference Call and Webcast Information

The Company will host a conference call and audio webcast today, Thursday, February 17^th at 8:30 a.m. Eastern Time featuring remarks by Christopher Ianelli, MD, PhD, CEO and President, Tracy Curley, CFO and Treasurer, and Jill Mullan, COO and Secretary.

Event:	iSpecimen Full Year 2021 Results Conference Call
Date:	Thursday, February 17, 2022
Time:	8:30 a.m. Eastern Time
Live Call:	+1-877-425-9470 (U.S. Toll Free) or + 1-201-389-0878 (International)
Webcast:	https://viavid.webcasts.com/starthere.jsp?ei=1526504&tp_key=09d0a0a925

For interested individuals unable to join the conference call, a replay will be available through March 3, 2022, at +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International). Participants must use the following code to access the replay of the call: 13726694. An archived version of the webcast will also be available on iSpecimen’s Investor Relations site: https://ispecimen.irpass.com/.

About iSpecimen
iSpecimen offers an online marketplace for human biospecimens, connecting life scientists in commercial and non-profit organizations with healthcare providers that have access to patients and specimens needed for medical discovery. Proprietary, cloud-based technology enables scientists to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. For more information about iSpecimen, please visit www.ispecimen.com.

Forward Looking Statements
This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements are characterized by future or conditional verbs such as “may,” “will,” “expect,” “intend,” “anticipate,” believe,” “estimate” and “continue” or similar words. You should read statements that contain these words carefully because they discuss future expectations and plans, which contain projections of future results of operations or financial condition or state other forward-looking information.

Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to the risks factors contained in the Company’s filings with the Securities and Exchange Commission, which are available for review at www.sec.gov. Forward-looking statements speak only as of the date they are made. New risks and uncertainties arise over time, and it is not possible for the Company to predict those events or how they may affect the Company. If a change to the events and circumstances reflected in the Company’s forward-looking statements occurs, the Company’s business, financial condition and operating results may vary materially from those expressed in the Company’s forward-looking statements.

Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Disclaimer Regarding Financial Information
The financial information presented in this press release is based on preliminary, unaudited financial statements prepared by management, for the year ended December 31, 2021. Accordingly, such financial information may be subject to change. All information contained in this press release will be qualified with reference to the audited financial results for the year ended December 31, 2021, which will be released on or before March 31, 2022, and will be posted on www.sec.gov. While the Company does not expect there to be any material changes to the financial information provided in this press release, any variation between the Company’s actual results and the preliminary financial information set forth herein may be material.

For further information, please contact:

Investor Contact
KCSA Strategic Communications
Allison Soss
iSpecimen@kcsa.com

Media Contact
KCSA Strategic Communications
Caitlin Kasunich / Raquel Cona
iSpecimen@kcsa.com

	iSpecimen Inc.
	BALANCE SHEETS
		December 31, 2021			December 31, 2020
		(Unaudited)
	ASSETS
	Current assets:
	Cash	$	27,738,979		$	695,909
	Accounts receivable - unbilled		1,739,020			652,761
	Accounts receivable, net of allowance for doubtful accounts of $269,170 and $108,096 at December 31, 2021 and December 31, 2020, respectively		3,002,442			1,526,392
	Prepaid expenses and other current assets		327,035			417,929
	Tax credit receivable, current portion		140,873			179,376
	Total current assets		32,948,349			3,472,367
	Property and equipment, net		32,781			75,589
	Internally developed software, net		2,710,867			2,634,139
	Security deposits		27,601			27,601
	Total assets	$	35,719,598		$	6,209,696
	LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)
	Current liabilities:
	Accounts payable	$	832,678		$	1,792,432
	Accrued expenses		1,009,803			810,910
	Accrued interest		8,167			3,696,944
	Convertible notes payable, related parties, net of unamortized debt discount and debt issuance costs		-			5,490,811
	Derivative liability for embedded conversion features on convertible notes payable		-			2,373,000
	Bridge notes payable, net of debt issuance costs		-			4,589,228
	Bridge notes payable, related parties		-			1,905,000
	Note payable, current portion		-			604,109
	Deferred revenue		654,746			873,254
	Total current liabilities		2,505,394			22,135,688
	Note payable, net of current portion		-			178,899
	Term loan		3,422,616			-
	Total liabilities		5,928,010			22,314,587
	Commitments and contingencies
	Series B convertible preferred stock, $0.0001 par value, 3,200,000 shares authorized, 0 and 572,465 shares issued and outstanding at December 31, 2021 and December 31, 2020, respectively		-			7,999,997
	Series A-1 convertible preferred stock, $0.0001 par value, 556,550 shares authorized, 0 and 100,365 issued and outstanding at December 31, 2021 and December 31, 2020, respectively		-			561,041
	Series A convertible preferred stock, $0.0001 par value, 3,427,871 shares authorized, 0 and 618,182 issued and outstanding at December 31, 2021 and December 31, 2020, respectively		-			2,612,038
	Total convertible preferred stock		-			11,173,076
	Stockholders' equity (deficit)
	Common stock, $0.0001 par value, 200,000,000 shares authorized, 8,764,479 issued, and 8,733,479 outstanding at December 31, 2021, and 16,000,000 shares authorized, 967,213 issued and 936,213 outstanding at December 31, 2020		873			94
	Additional paid-in capital		67,810,289			1,779,698
	Treasury stock, 31,000 shares at December 31, 2021 and December 31, 2020, at cost		(172	)		(172	)
	Accumulated deficit		(38,019,402	)		(29,057,587	)
	Total stockholders' equity (deficit)		29,791,588			(27,277,967	)
	Total liabilities, convertible preferred stock and stockholders' equity (deficit)	$	35,719,598		$	6,209,696

iSpecimen Inc.
STATEMENTS OF OPERATIONS
	Year ended December 31,
		2021				2020
	(Unaudited)
Revenue	$	11,135,303			$	8,184,106
Operating expenses:
Cost of revenue		5,249,013				3,585,477
Technology		1,837,882				1,465,348
Sales and marketing		2,422,743				1,783,563
Supply development		573,913				497,182
Fulfillment		1,363,522				859,643
General and administrative		5,613,476				2,399,273
Total operating expenses		17,060,549				10,590,486
Loss from operations		(5,925,246	)			(2,406,380	)
Other expense, net
Interest expense		(2,102,681	)			(2,096,795	)
Change in fair value of derivative liability on convertible notes		(271,000	)			(159,000	)
Change in fair value of derivative liability on bridge notes and bridge notes, related parties		1,582,700				-
Gain (loss) on extinguishment of bridge notes and bridge notes, related parties		(2,740,425	)			-
Loss on extinguishment of convertible notes and convertible notes, related parties		(260,185	)			-
Gain on extinguishment of note payable		788,156				-
Other income		-				9,654
Other expense, net		(44,531	)			-
Interest income		11,397				437
Other expense, net		(3,036,569	)			(2,245,704	)
Net loss before benefit from income taxes		(8,961,815	)			(4,652,084	)
Benefit from income taxes		-				-
Net Loss	$	(8,961,815	)		$	(4,652,084	)
Net loss per share
Basic and diluted	$	(2.09	)		$	(4.97	)
Weighted average common shares outstanding
Basic and diluted		4,287,424				936,213

FAQ

What were iSpecimen's revenue results for FY 2021?

iSpecimen reported FY 2021 revenue of $11.1 million, a 36% increase from $8.2 million in FY 2020.

How much funding did iSpecimen raise in December 2021?

iSpecimen raised $21 million in a private placement in December 2021.

What was the net loss for iSpecimen in FY 2021?

The net loss for iSpecimen in FY 2021 was approximately $9.0 million, up from $4.7 million in FY 2020.

How did iSpecimen's revenue mix change in FY 2021?

In FY 2021, 72% of revenue was from non-COVID-19 related sources, compared to 57% in FY 2020.

What significant operational milestones did iSpecimen achieve in 2021?

iSpecimen expanded its supplier network to 200 organizations and increased unique customer organizations to 415.